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Many exciting events have occurred in the last 40 years in
the field of valvular heart disease . Valve surgery continues
to remain the dominant therapeutic modality in the manage-
ment of patients with severe symptomatic valve lesions ; a
	
valve replacement .
previous perspective in 1 83 was mainly de-
voted to that topic (1) . In the last 7 years, new
developments (for example, catheter balloon
valvuloplasty for stenotic valve lesions [2]) or
additional data (for example, from two random-
ized trials of prosthetic heart valves, better _
analysis of results of valve surgery and value of
various tests [3-5]) have resulted in a reassess- A N N I V E
ment of some aspects of the management of 1
 
4
 
adult patients with valvular heart disease . This
perspective will focus on these and other aspects not cov-
ered in the previous perspective (1) .
Determinants of Results of Valve Surgery
Factors influencing surgical results (Table 1) . About 15
years ago, it was recognized that the preoperative clinical
condition of the patient and the intraoperative care influ-
enced the results of valve surgery (6,7) . Subsequent studies
have demonstrated that 1) The etiology of mitral regurgita-
tion influenced the results of mitral valve replacement (8) . 2)
Patients operated on at different periods, at the same center
by the same surgeons using the same prosthetic valve
device, had different outcomes ( ,10) . This was called the
"time factor" ; time factor, that is, time as a variable, includes
differences in the clinical condition, ventricular function and
cardiovascular function of patients, in medical treatment, in
operative techniques and in pre- and postoperative care (3) .
3) Analysis from a large data base (11) showed that valve-
related complications are more importantly related to pa-
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tient-related factors than to the type of prosthesis that was
used. 4) Factors other than the type of prosthesis used were
more important in determining the intermediate results of
For example, in the Edinburgh (5) and
Veterans Administration (4) randomized clinical
trials, which compared a mechanical prosthetic
valve with a bioprosthetic valve, showed that up
to 7 years after surgery there were no significant
differences in the results with regard to survival,
reoperation and valve-related complications .
The Veterans Administration study (4) also
showed that 1) there was no clinically meaning-
RSARY
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ful or statistically significant difference in the
hemodynamics of various commonly used sizes
of a tilting-disc mechanical and bioprosthetic valves (12) ;
and 2) the effects of valve replacement on hemodynamics
and left ventricular function are influenced by patient-related
factors (13 and Crawford MH, personal communication) .
The type of surgery (for example, valve repair versus
replacement) may influence the results of' surgery (l4) .
Certain complications, for example, mechanical failure, de-
generation, thrombosis and need for anticoagulation, vary
with different prostheses (15)   and thus, the type of prosthe-
sis also influences the results of valve surgery .
Quality of surgical treatment (Table 2). The preoperative
clinical condition of the patient may be influenced by health
care delivery factors . The Veterans Administration study (4)
showed that the ratio of observed to expected operative
mortality varied greatly among the participating centers ; in 5
of the 13 centers this ratio was > 1, indicating that the quality
of surgical treatment also influences patient outcome (16) .
This article is part of a series of articles celebrating the
40th anniversary of the American College of Cardiology .
The series attempts to set the stage for the future
by
describing current state of the art management of selected
major cardiovascular problems and the basic knowledge
that will provide directions for advances in diagnosis and
therapy .
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Table 1 . Factors That Influence Valve Surgery
Results of valve surgery with regard to
Survival
Complications
Valve function
Cardiac function
Functional class
Are dependent on
Patient-related factors
Type of surgery
Type of prosthesis
Health care delivery factors
Reprinted by permission of the American Heart Association, Inc . (Ref . 3).
Health care delivery factors are multiple, complex and
interrelated (3) . Some factors, for example, early diagnosis
and treatment of complications of prosthetic valves, are
uniquely related to valve disease . Anticoagulant therapy
that is inappropriate (17), inadequate or incorrectly dis-
continued may also hav' ? mqior impact on the observed
results .
Associated Coronary Artery Disease
Coronary bypass surgery plus valve surgery (Table 3) . It
was previously emphasized (1) that patients who have asso-
ciated coronary artery disease should undergo simultaneous
coronary bypass surgery and valve replacement because 1)
the combined procedure can be performed at only a slightly
higher risk than that of valve replacement alone ; 2) the 10
year survival of patients undergoing the combined procedure
was only a little less than that of patients without associated
coronary artery disease who underwent isolated valve re-
placement ; 3) large randomized trials of coronary bypass
surgery for isolated coronary disease had demonstrated an
improved survival in several subsets of patients ; and 4) there
were obvious difficulties in performing an adequate random-
ized trial of bypass surgery in patients undergoing valve
replacement .
Recent data (18) showed that the operative mortality of
patients with associated coronary artery disease who did not
undergo coronary bypass surgery with aortic valve replace-
ment was increased and the 10 year survival was reduced
(Table 3) . In that study, patients who underwent surgery
for associated coronary artery disease had more extensive
coronary disease than did those who did not (Table 3) ;
therefore, the improvement in 10 year survival in those
undergoing coronary bypass surgery would have been
greater had the patients in the two groups been compar-
able . At present, all patients undergoing valve surgery
should have myocardial revascularization for associated
coronary artery disease except in special clinical circum-
stances .
Indications for coronary arteriography . The joint Task
Force of the American College of Cardiology/American
Table 2. Health Care Delivery Factors That Influence
Results of Surgery
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Preoperative management
Time patient seeks medical care
Patient acceptance of and complicance with diagnostic and therapeutic
measures
Expertise of care provided by family practitioners, internists and
cardiologists
Timing of referral for specialized cardiac investigation and interventional
treatment
Expertise in nonsurgical intervention treatment
Quality of surgical management
Expertise of anesthesia team
Expertise of surgical team
Surgical techniques
Expertise in perioperative care
Postoperative management
Expertise in long-term care of patients after interventional therapy
Early diagnosis and treatment of complications
Specialized care with certain treatments (e .g ., anticoagulants)
Patient cooperation and compliance with long-term care
Reprinted by permission of the American Heart Association, Inc . (Ref . 3) .
Heart Association (1 ) had issued guidelines for perform-
ing coronary arteriography in patients with valvular heart
disease. For skilled and experienced coronary arteriogra-
phers working in experienced cardiac catheterization
laboratories, one could recommend that coronary arteriog-
raphy should be performed in all patients who are being
considered for valve surgery or who are undergoing left
heart catheterization for valvular heart disease if they are
>_35 years of age or have symptoms or signs suggestive of
coronary artery disease or have one or more major risk
factors for coronary disease .
Incidence of associated coronary artery disease . This will
vary considerably depending on the prevalence of coronary
artery disease in the population that is being studied . In our
studies at the University of Oregon (20,21), the incidence of
associated coronary artery disease was about 35% in pa-
tients with aortic stenosis, 20% in patients with aortic
regurgitation and 45% in patients with aortic stenosis who
were aged ?60 years . In the Veterans Administration Coop-
erative Study on Valvular Heart Disease (16), 42  (48%) of
8 6 patients had ?50% stenosis of one or more coronary
arteries ; in those with coronary artery disease, the incidence
of one, two and three vessel disease was 36%, 31% and 33%,
respectively .
Clinician Decision-Making
Clinical evaluation . There are usually several steps in-
volved in clinical decision-making in patients with valvular
heart disease (Table 4) (22) . The first and most important is
a complete clinical evaluation that includes the history,
physical examination, electrocardiogram and chest roent-
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Table 3. Effect of Coronary Bypass Surgery and Aortic Valve Replacement on Operative Mortality and Late Survival
genogram. At the end of this evaluation, the clinician should
diagnose and assess the severity of disease of all valves,
assess the state of ventricular function, evaluate the hemo-
dynamic effects of the valvular disease and associated ven-
tricular dysfunction, evaluate the extent and severity of
coronary artery disease and diagnose the presence or ab-
sence of other cardiovascular disease . Additionally, it is
necessary to make an evaluation of the effects of the
cardiovascular disease on other body organs and also to
make a complete evaluation of disease in other organ sys-
tems of the body .
Decisions on indications for diagnostic tests . The next step
is an important one   the clinician should list, either in writing
or in thought, the questions that need answering in that
particular patient and also why these questions need to be
answered . After this, one makes the critical decision about
performing tests that are most likely to provide answers to
Table 4. Steps in Clinical Decision-Making in Patients With
Valvular Heart Disease
1) Complete clinical evaluation
History
Physical examination
Electrocardiogram
Chest roentgenogram
2) Diagnose and assess severity of disease of
All valves
Ventricular function
Hemodynamic effects
Coronary artery disease
Other cardiovascular disease
Effects on other body organs
Other organ diseases
3) List questions that need answering
4) Be reasonably certain these questions need to be answered
5) Perform tests most likely to provide these answers in one's own
institution with the following criteria
Reliability
Accuracy
Lowest risk to patient
Reasonable (or lowest) cost
6) Review results of test(s)
7) Make an overall assessment of patient
8) Make recommendations regarding management
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AVR = aortic valve replacement   CAD = coronary artery disease   CBS = coronary bypass surgery   Pts = patients   VD = vessel disease . (Data from Journal
of the American College of Cardiology [18] .)
these questions reliably, accurately, at the lowest risk to the
patient and at a reasonable cost in one's own institution .
Depending on the clinical circumstances, the decision to
perform the tests may be stepwise, rather than an across the
board ordering of several tests . As the results of each test
become available, an overall reevaluation and reassessment
and a decision about the need for further tests is made .
Finally, when all the information from the various tests is
available, a complete evaluation of the patient is made and
recommendations regarding management of the patient fol-
low. Subsequently, these recommendations are discussed
with the patient .
Results of clinical decision-making . The results of a pro-
spective, blinded clinical decision-making study of  8 con-
secutive patients with valvular heart disease are shown in
Table 5 (23,24) . The results from cardiac catheterization and
angiography and the subsequent clinical decision that was
made were considered 100% correct . The most important
finding of the study is how commonly the initial clinical
evaluation was correct . Lembo (25) and Crewe (26) and
coworkers have demonstrated and emphasized the feasibil-
ity and practicality of diagnosing at the bedside the etiology
of cardiac murmurs by dynamic auscultation . Both studies
(23-26) emphasize the importance of learning and practicing
the cognitive skills and becoming excellent at clinical eval-
uation .
Rheumatic Fever and Carditis
In recent years there have been several reports (27-30) of
outbreaks of acute rheumatic fever in Salt Lake City,
northeast Ohio, the tristate area of western Pennsylvania
and at a naval training center in San Diego, California . The
patients have been predominantly (? 0%) white, middle
class and from nonurban areas . Genetic predisposition
and emergence of strains of group A streptococcus more
likely to produce rheumatic fever have been suggested as
predisposing to the reemergence of this disease (31-33) . An
increased awareness of the diagnosis and management of
rheumatic fever and primary and secondary prevention of
recurrences of rheumatic fever and carditis are critical
(34-36) .
1 82-83 1 67-76
Operative
Mortality (%)
Operative
Mortality (%)
10 Year Survival
All Pts (%) IVD (%) 2VD (%) 3VD 1%) LMCAD (%)
AVR + no CAD 1 .4 4 .5 63 - - -
AVR + CAD + CBS 4 .0 6 .3 4  38 28 34 II
AVR + CAD + no CBS   .4 10 .3 36 65 22 13 1
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Table 5 . Results of a Prospective, Blinded Clinical Decision-Making Study of Consecutive Patients
With Valvular Heart Disease
Echo/Doppler = Echocardiography/Doppler study .
Aortic Stenosis
Natural History
Severe aortic stenosis . Ross and Braunwald (37) reviewed
seven autopsy studies published before 1 55 and conclud-
ed that in aortic stenosis the average life expectancy after
the onset of symptoms was 3 years ; after the occurrence
of angina it was 5 years, after syncope 3 years, and after
the onset of heart failure <2 years . They documented
that 15% to 20% of deaths in patients with aortic stenosis
were sudden; 65% to 80% of sudden deaths had occurred
in symptomatic patients . Although this was a retro-
spective postmortem review of patients who had died
Sensitivity and Specificity of Diagnosis of the Presence of a Valvular Lesion
Accuracy of Diagnosis Including Severity of the Valvular Lesion
Accuracy of Diagnosis for Moderate or Severe Valvular Lesions
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before the use of left heart catheterization, it is interesting
how close these estimates may be to the true outcome
in these patients. In a prospective study of 35 patients
who had an aortic valve area <0 .8 cm2 documented by
cardiac catheterization and who had refused surgery, Horst-
kotte and Loogen (38) demonstrated that the average sur-
vival after the onset of symptoms was 23 months ; the mean
survival after the occurrence of angina was 45 months, after
syncope 27 months and after onset of the left heart failure 11
months .
In the study of Frank et al . (3 ) of 15 patients aged 32 to
5  years with a catheterization-proved aortic valve area <_0 .7
After Clinical Evaluation After Echo/Doppler
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Final diagnosis
Aortic stenosis 78  2 100  2
Aortic regurgitation 66 76 7  74
Mitral stenosis
86 87  4 8 
Mitral regurgitation 75 88 82 80
Accuracy of Recommendations for Valve Surgery
After Clinical
Evaluation (%)
After Echo/
Doppler (%)
Final recommendation
Aortic valve replacement 61 58
No aortic valve replacement 84
 0
Mitral valve replacement 58 50
No mitral valve replacement
or commissurotomy 76 76
After Clinical
Evaluation (%)
After Echo/
Doppler (%)
Final diagnosis
Aortic stenosis
48
65
Aortic regurgitation 43 57
Mitral stenosis 44 52
Mitral regurgitation 50 46
After Clinical
Evaluation (%)
After Echo/
Doppler (%)
Final diagnosis
Aortic stenosis 100 100
Aortic regurgitation  1
100
Mitral stenosis  2  7
Mitral regurgitation
 7
100
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who were treated nonsurgically because they had
refused surgery, the 3, 5 and 10 year mortality rate was 36%,
52% and  0%, respectively . Rapaport's report (40) of severe
aortic stenosis (aortic valve area stated to be_ 1 .0 cm2 )
showed a 5 and 10 year mortality rate of 62% and 80%,
respectively . Chizner et al . (41) reported on 23 patients (peak
to peak catheter gradient 6  ± 33 mm Hg, mean ± SD)
whose mortality rate at 1, 2, 5 and I I years after the onset of
symptoms was 26%, 48%, 64% and  4%, respectively .
Schwarz et al
. (42) reported on 1  patients, aged 56 ± 8 .3
years, who were in New York Heart Association functional
class III or IV and had refused surgery. Their peak to peak
transvalvular gradient was 8  .6 ± 17.3 mm Hg, mean left
atria] pressure 13 .3 ± 11 .  mm Hg, left ventricular end-
diastolic volume index 122.8 ± 58.3 ml/m2 and ejection
fraction 57.4 ± 12 .8%. The 3 year mortality rate of the 1 
patients was 7 % .
O'Keefe et al. (43) reported on 50 patients evaluated from
1 78 through 1 85, of whom 28 refused surgery and 22 had
surgery deferred by the physician because of "perceived
excessive surgical risk ." In 30 (60%) of the 50 patients,
"precise" quantification of severe aortic stenosis was ob-
tained by Doppler echocardiography, cardiac catheteriza-
tion, or both . In 15 patients, the mean maximal Doppler
instantaneous gradient was 81 mm ft and in 20 patients,
cardiac catheterization data yielded an aortic valve area of
0.3 to 0 .8 cm 2 . The patients' average age was 77 years, 20
were >80 years old ; 65% of those undergoing angiography
had coronary artery disease . The 1, 2 and 3 year mortality
rate was 43%, 63% and 75%, respectively .
Kelly et al. (44) reported on 3  symptomatic patients, of
whom 26 refused surgery and 13 did not undergo it because
the "supervising physician did not deem symptoms to be of
sufficient severity to warrant surgery ." The patients had a
mean age of 72 ± 11 years (range 5  to  8) and a Doppler
peak gradient of 68 ± 1  mm Hg (range 50 to 115) . The I year
mortality rate was about 38% . Horstkotte and Loogen (38)
reported on 35 patients with an aortic valve area <0 .8 cm2 at
cardiac catheterization who refused surgery . Their mean
survival time was 23 ± 5 months, the 5 year mortality rate
was 82 ± 7%, and all patients died within 12 years .
It is clear that symptomatic severe aortic stenosis is
associated with a high or a very high mortality rate when
managed medically ;
the mortality is much higher than that of
many malignant neoplasms . Therefore, before denying pa-
tients interventional therapy for symptomatic severe aortic
stenosis, physicians have to very carefully weigh the risks
and benefits of interventional and noninterventional therapy ;
these must also be discussed with the patient and family .
Mild aortic stenosis . Horstkotte and Loogen (38) fol-
lowed up 142 patients after cardiac catheterization who had
an aortic valve area > 1 .5 cm 2 , which they called mild aortic
stenosis . At 10 year follow-up, aortic stenosis was mild in
88% and moderate in 4% ; 8% had undergone aortic valve
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replacement . At 20 years, aortic stenosis was still mild in
63% and moderate in 15% ; 22% had undergone aortic valve
replacement or had severe stenosis . At 25 years, aortic
stenosis was mild in 38% and moderate in 25% ; 38% had
undergone aortic valve replacement. In view of this "fa-
vorable" natural history, it is clear that patients with an
aortic valve area >1 .5 cm2 ("mild" stenosis) should not
undergo valve surgery or other interventional therapy .
Moderate aortic stenosis . It is difficult to know the natural
history of truly moderate aortic stenosis because of varying
definitions that have been used to classify moderate stenosis
(see later) . Horstkotte and Loogen (38) defined it as an aortic
valve area of 0 .8 to 1 .5 cm2 and an aortic valve gradient of
X80 mm Hg   most centers would consider that at least some
of the patients in this group had severe aortic stenosis . In
this mixed group of patients with moderate and severe aortic
stenosis, in whom the incidence of moderate and severe
stenosis is not known, approximately 5% had developed
severe stenosis and about 25% had undergone aortic valve
replacement at the end of 10 years .
Chizner et al . (41) defined moderate aortic stenosis as an
aortic valve area of 0 .71 to 1 .0  cm' and a systolic peak
gradient <70 mm ft however, 6 of their 10 patients with
"moderate" stenosis died in an average time of   months
(range 2 days to 22 months) . Thus, it may be clinically
imprudent to consider all patients with an aortic valve area
of 0 .71 to 1 .0 cm2 as having "moderate" stenosis (see later) .
Asymptomatic severe aortic stenosis . Ross and Braunwald
(37) concluded that 3% to 5% of deaths in acquired aortic
stenosis occurred suddenly in asymptomatic patients . In the
study of Frank et al . (3 ), three patients with severe aortic
stenosis were asymptomatic ; 1 (33%) died suddenly 1 
months after cardiac catheterization. In the study of Horst-
kotte and Loogen (38), 3 patients died suddenly before the
onset of symptoms and 10 were asymptomatic at the start of
the study (personal communication) ; thus, 3 (30%) of 10
asymptomatic patients died suddenly before the onset of
symptoms .
Chizner et al . (41) studied eight asymptomatic patients
aged 20 to 2  years with "moderate" and "severe" aortic
stenosis . At an average follow-up interval of 60 months, five
had undergone aortic valve replacement and three had
remained asymptomatic . Kelly et al . (44) studied 51 asymp-
tomatic patients aged 63 ± 1  years with "moderate" and
"severe" aortic stenosis . At an average follow-up time of
only 17 ±   months, 41% of the patients became symp-
tomatic and 16% died . Of the eight deaths, two were sudden
(both occurred after the onset of symptoms), five were from
carcinoma and one was from Osler-Weber-Rendu syndrome .
Both of these series included patients who had moderate as
well as severe stenosis and five of the eight deaths in the
series of Kelly et al . (44) were from carcinoma, an interesting
chance occurrence .
More prospective studies are needed of asymptomatic
6	
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patients with aortic stenosis in which the severity of stenosis
is well documented and results of moderate and severe
stenosis are presented separately . From the available data, it
seems likely that the outcome of asymptomatic patients with
severe aortic stenosis is not necessarily benign .
Grading the Degree of Aortic Stenosis
Peak gradient versus valve area . Many different criteria
have been used to define severe aortic stenosis   an aortic
valve area <_0 .5 cm' (45), <_0.7 cm 2 (46), -0.75 cm' (47-50),
 S 1 .0 cm- (40), <_0.70 cm'-/m'- (3 ,51), <_0 .6 cm'-/m- (52) and
<_0 .40 cm'/m' (4 ,50) . One of the more commonly used
criteria is a peak systolic gradient >_50 mm Hg (51)   this
gradient may not have a very good direct relation to the
orifice size . It is recognized that in most adults a high peak to
peak systolic gradient (for example . >60 mm Hg) usually
signifies severe aortic stenosis ; however, a gradient from 20
to 5  mm Hg may signify mild, moderate or severe stenosis .
For any size of stenotic aortic valve, the systolic gradient is
determined by the stroke volume and systolic ejection period
(53), both of which are dependent on the loading conditions
and contractile state of the left ventricle, and resistance in
the arterial system (54) . Moreover, the stenotic valve area is
inversely related not to the mean systolic gradient but to the
square root of the mean systolic gradient (53) . Thus, it seems
best to define severe aortic stenosis in terms of valve area .
Also, people of different body size need different sizes of
aortic valve area ; therefore, it is best to correct the valve
area for body surface area (55) . Although calculation of
valve area by the method of Gorlin and Gorlin (52) was
criticized 36 years ago (56), it is still widely used, is clinically
useful and has stood the test of time .
Valve area diagnostic of severe stenosis . Braunwald and
Morrow (51) defined severe aortic stenosis as an aortic valve
area index <_0 .70 cm'/m' (51) . The subsequent natural his-
tory study of Frank et al . (38) (see aforementioned) used this
criterion ; however, all the patients in this study had a valve
area index of <--0 .63 cm
2/M2  
thus, this criterion (<_0 .63 to
0.70 cm'/m2 ) now has the backing of a natural history study .
Tobin et al . (52), on the basis of left ventricular stroke work
loss of >_30% and knowledge that an orifice must be reduced
to <_25% of its natural size before serious consequences
occur (57,58), showed that aortic stenosis was severe when
the valve area was X0 .7 to 1 .0 cm' or <_0.4 to 0.6 cm'/m' .
The aortic valve area values from these two studies are very
close (<0.63 and X0 .60 cm'/m', respectively)   the value of
<_0 .6 cm'/m' is equal to <_ 1 .0 cm 2 . assuming an average body
size of 1 .75 m 2 .
Rapaport (40) assumed severe aortic stenosis when valve
area was <_ 1 .0 cm' but in his natural history study it is not
clear how this value was obtained in the patients . The other
investigators provide no rationale for the criteria they used
in assessing severe aortic stenosis . The natural history study
JACC Vol . 14, No . I
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Table 6
. Suggested Grading of the Degree of Aortic Stenosis
*Patient with an aortic valve area that is at a borderline value between the
moderate and severe grades (0
.  to 1 .1 cm'   0 .55 to 0 .65
CM'/M2)
should be
individually considered for reasons discussed in the text . AVA = aortic valve
area .
reported by Horstkotte et al . (38) provides a reasonable basis
for considering a calculated aortic valve area of > 1 .5 em 2 as
mild stenosis .
The investigators who consider that only an aortic valve
area of X0 .8, <_0 .75 or <_0.7 cm' indicates severe aortic
stenosis would have to consider patients with a valve area of
>0.8. >0.75 or >0.7 cm 2 up to 1.0 or 1 .1 cm' as having
moderate stenosis . The study of Chizner et al . (41) shows
that symptomatic patients with an aortic valve area of 0 .71 to
1 .0  cm 2 had a very poor outcome ; 60% died in an average
time of   months (range 2 days to 22 months) and another
20% underwent aortic valve replacement . This outcome can
hardly be considered as consonant with moderate stenosis ;
most of these patients should be considered as having severe
aortic stenosis .
A grading schema for aortic stenosis . A suggested schema
for grading severity of aortic stenosis in adults is shown in
Table 6 . Aortic valve areas, particularly those with border-
line values between the moderate and severe grades (0 .  to
1 .1 cm 2 , 0 .55 to 0 .65 cm'/m'), should be interpreted in
association with other clinical features because of several
factors   1) the accuracy of the calculated aortic valve area is
dependent on the care with which the gradient and flow
measurements are made and the values calculated ; 2) in an
individual patient the normal value for aortic valve area is
unknown   3) body size is one important variable ; and 4) the
constant in the Gorlin formula may not be accurate in an
individual clinical circumstance .
Doppler Echocardiography Versus Cardiac
Catheterization,for Assessing Severity of
Aortic Stenosis
Doppler versus catheterization valve gradient . A number
of studies have compared the relation of gradient and aortic
valve area obtained by Doppler echocardiography with that
obtained by cardiac catheterization and have shown that the
r value of the relation is ?0.8. Importantly, one needs to
know the precision (or the confidence limit) of a value
obtained by the noninvasive method, which is determined
from the standard error (SE) of the regression equation (Fig .
I) . Thus, even if the Doppler gradient of 50 mm Hg is equal
Aortic Slenosis
AVA
(cm'- ) AVA Index (em'/m')
Mild > 1 .5
>0 . 
Moderate 1 .1 to 1 .5 --0 .6 to 0 . 
Severe* _<0 .8 to 1 .0 <_0 .4 to 0 .6
	1 I	
f	t I
10 20 30
40
50 60 70 80  0 100
MEAN SYSTOLIC GRADIENT (mmHg)
CARDIAC CATHETERIZATION
Figure 1 . Hypothetical relation of Doppler mean systolic aortic
valve gradient to that obtained by cardiac catheterization . Even
though the gradients by Doppler and by cardiac catheterization are
identical at 50 mm Hg by regression equation, values of 2 SE show
that when the Doppler gradient is 50 mm Hg, the  5% confidence
limit predicts that the gradient by cardiac catheterization is likely to
be between 30 and 70 mm Hg .
to 50 mm Hg on cardiac catheterization from the regression
equation and I SE is 10 mm Hg, then the  5% confidence
limit (2 SE) would estimate that, in this instance, when the
Doppler gradient is 50 mm Hg. the gradient obtained from
cardiac catheterization is likely to be between 30 and 70 mm
Hg (Fig . 1) . The range of 2 SE of the regression equation of
aortic valve gradients and of valve area from several studies
is shown in Table 7 . Ideally, one should know the relation of
Doppler gradient and valve area to cardiac catheterization
Table 7. Relation of Doppler to Cardiac Catheterization Gradient and Valve Areas
in Aortic Stenosis
*Same medical center .
findings at one's own institution, which should be simulta-
neously obtained prospectively in a blinded study of a
significant number of consecutive patients ; in one such study
(5 ) 2 SE of the regression equation was 20 mm Hg . Some
conservative general guidelines for estimating severe aortic
stenosis from Doppler gradients are shown in Table 8 .
Factors determining measurement accuracy . Doppler es-
timation of the pressure drop across a stenotic valve depends
on the application of Bernoulli's law for the calculation of
valve area . Energy losses, nonuniform velocity profiles,
pressure recovery, unsteady flow and omission of the up-
stream velocity affect the accuracy of the Doppler estimate
(71) . The simplified Bernoulli equation used in Doppler
estimates does not completely describe the relation between
the pressure drop at the inlet of the obstruction and the
Doppler velocity measurement (71) ; these are some reasons
for the discrepancy between the measurements obtained by
Doppler technique and those obtained at cardiac catheter-
ization . Another reason is that the quality of the Doppler
signal is clearly operator dependent (5 ,72) . and even at a
2 SE of Regression Equation Estimate
Cited Author Ref.
No . of
Patients
Mean Aortic Valve
Gradient (mm Hg)
Aortic Valve
Area (cm'- )
Currie et al .* 5  100 20
Skjaerpe et al . 60 30 18
16 to 30 0.20 to 0 .42
Krafchek et al . 61 3 
18
Currie et al .*
62
62 16
Smith et al . 63 40 12
Yeager et al . 64 58
-
Zoghbi et al . 65
3  - 0.22 to 0 .30
Otto et al . 66
48 24 0 .80
Teirstein et al . 67 30 16 0 .34
Come et al . 68
31 - 0 .32
Oh et al .* 6  100
20 0 .38
Nishimura et al
.* 70 55 0.20 to 0 .34
Range 12 to ±24
±0 .20 to ±0 .80
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too-
Table 8. Suggested Conservative Guidelines for Relating Doppler
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Figure 2 . Relation of mean systolic aortic valve gradient by Dopp-
ler echocardiography (panel A) to that obtained by cardiac catheter-
ization (Cath) at the same medical center at two different times
(panel B) . Note the different regression equations in each panel . In
panel B, a Doppler gradient of approximately 35 to 40 mm Hg is
associated with cardiac catheterization gradient of approximately 25
to 70 mm Hg . (Reproduced by permission of the American Heart
Association [panel A (5 )] and the American College of Cardiology
[panel B (6 )1 .)
single excellent medical center the regression equation can
vary at different times (Fig . 2) . Similarly, the care with which
gradient and flow measurements are made at cardiac cathe-
terization and the values calculated will affect the results .
Catheter Balloon Valvuloplasty
Evaluating the results. Since November 1 86 (2), there
has been a great increase in the number of patients who have
undergone balloon valvuloplasty . We do not yet know the
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Table   . Aortic Valve Areas Before and After Catheter Balloon Valvuloplasty
0 n 50 75
Cath, mm Hg
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full extent of the results that can be achieved, the complica-
tions, late survival and the clear definition of those who will
be benefited and those who will not . Nevertheless, a few
observations are worth emphasizing at this time
1 . Aortic valve area   a) The average valve area achieved
after balloon valvuloplasty (Table  ) is not different now
from that which was reported earlier (0 .8, 0.  cm 2) (2) ; b) the
increase in average valve area is 0 .3 to 0 .4 cm 2 (Table  ),
although most centers have cases in which the increase has
been greater (0 .5 cm 2 , at times 0 .6 cm2) (Fig . 3) ; and c) those
patients who have a larger aortic valve area after valvulo-
plasty frequently have a larger valve area before valvulo-
plasty (Table 10) .
2 . Restenosis may occur quite rapidly (70,73) ; at an
average follow-up period of 6 months, it may be as high as
65% or 77% (75,7 ). Restenosis rates are higher when the
final aortic valve area after valvuloplasty is <0 .7 cm 2 and
when the increase in valve area is small (75,80) .
3 . The hospital mortality rates range from 7% to 13%
*Multi-Hospital Eastern Atlantic Restenosis Trial   tMansfield Scientific Aortic Valve Registry (many patients in
this registry are probably also included in the other series) . Values are mean ± SD . AVA = aortic valve area ; CBV
= catheter balloon valvuloplasty
.
Cited Author Ref .
No . of
Patients
Aortic Valve Area (cm'
- )
Increase of
Average AVA
by CBV
Pre-CBV
Post-CBV
Nishimura et al .
70 55 0 .54 ± 0 .15 0 .85 ± 0 .23 0.31
Safian et al . 73 170
0 .6 ± 0 .2 0 .  ± 0 .3 0 .3
Cribier et al . 74 350
0.47*_0 .14 0 .  ± 0 .02 0 .43
Block et al
.
75 162 0.5 ± 0 .01
0 .  ± 0.02 0 .4
M-Heart Group* 76
166 0.5 ± 0 .17 0.77 ± 0.24 0.27
MSAVRt
77
Before July 1 87 285
0 .5 ± 0 .18 0 .8 ± 0 .3 0 .3
July to December 1 87 231
0.4  ± 0 .17 0 .82 ± 0 .31 0 .33
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Figure 3 . Catheter balloon valvuloplasty (CBV) for
severe aortic (AO) stenosis with carcinoma of lung
with metastases in a patient in functional class IV .
Balloon valvuloplasty resulted in an increase of aortic
valve area of 0 .5 cm
2
from 0 .5 to 1 .0 cm 2 with rapid
relief of symptoms . The patient was discharged from
the hospital and died suddenly (cause of death un-
known) 4 months later. Balloon valvuloplasty played
an important palliative, supportive therapeutic role in
this patient . BUN = blood urea nitrogen; ECG =
electrocardiogram ; PULM ART PR = pulmonary ar-
tery pressure . (Reproduced by permission of Daniel L .
Kulick, MD, Veterans Administration Medical Cen-
ter, Albuquerque, New Mexico .)
(70,81,82); the "procedure mortality" rate may be 3% to 5%
(70) .
4 . Major complications, including death, may occur in
25% of patients (81) .
5 . Mortality at an average follow-up period of 6 months
ranges from 15% to 22% (70,73) . At I year, the actuarial
mortality rates are 24% (83), 43% (84) and 60% (85) ; about
25% of patients have undergone repeat balloon valvuloplasty
or aortic valve replacement . Late mortality (average 16
months) appears to be related to small valve area before and
after valvuloplasty, particularly if <0 .7 cm 2 . and to a lower
left ventricular ejection fraction (80,84,85) .
6 . In patients with impaired left ventricular function, the
results have been mixed, Desnoyers et al . (86) reported on
two patients with "cardiogenic shock" from severe aortic
stenosis (valve area 0 .2 cm 2 ) ; balloon valvuloplasty which
resulted in a final valve area of 0 .6 and 0 .5 cm 2 , respectively,
had a dramatic impact on the patient's immediate clinical
condition ; both patients rapidly came out of shock . Of 28
patients reported on by Safian et al . (87), 13 (46%) had a
major improvement in ejection fraction, whereas the remain-
PRE-CBV
Table 10 . Range of Aortic Valve Area After Catheter Balloon Valvuloplasty
*Not given in abstract
. CBV = catheter balloon valvuloplasty .
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POST -CBV
der had no change . The 55 patients reported on by Berland et
al . (88) had a 1 year actuarial mortality rate of 40% .
Clinical implications . These results must be kept in per-
spective. The average age of the patients in these series has
ranged from 77 to 80 years ; most patients were in clinical
class III or IV and were considered to be inoperable or at
very high risk for surgery ; many had associated coronary
artery disease . It is uncertain with which group of patients
treated medically or surgically the results from this cohort of
patients can be compared ; it is important to avoid making
inappropriate comparisons and conclusions (3) .
These results are also not surprising . It was pointed out
very early in the experience with balloon valvuloplasty that,
in view of the limited and modest increase in valve area with
this procedure, it may not result in the beneficial effects
achieved by valve replacement on symptomatic status, he-
modynamics . left ventricular function and survival (2) ; the
average aortic valve area achieved (Table  ), that is, 0 .8 to
0.  cm 2 , is still in the range of severe aortic stenosis . After
balloon valvuloplasty, 40% of patients have a valve area of
<0.7 cm 2 , which represents very severe stenosis that is
Cited Author Ref .
Aortic Valve Area (cm'- )
No . of
Patients )%)Pre-CBV Post-CBV
Cribier et al . 78 0.5 ± 0 .1 0 .8 ± 0
.1 13  (68)
0 .7 ± 0 .2 1 .3 ± 0 .3
6 (32)
Block and Palacios 75
No change from pre-CBV 614)
<0 .7
62 (3 )
*
0 .8 . 0 .  51 (32)
*
>l
.0
40(1-5)
CARDIAC OUTPUT
MEAN AO VALVE GRADIENT
AORTIC VALVE AREA
2
.7 L/min
1 .4 L/min/m2
36 mm Hg
0
.5cm2
3 .1 L/min
1 .6L/min/m 2
11 mm Hg
1 .Ocm2
O.26cm 2/m 2 0.52 cm 2
/m 2
PULM. ART. PR  
74/46mmHg
RIGHT ATRIUM  
BUN AND CREATININE  
13mmHg
47 and 2 .4
FUNCTIONAL CLASS
IV II+
Discharged from hospital 5 days later
Sudden death 4 months later
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Table 11 . Suggested Indications for Catheter
Balloon Valvuloplasty
A. Severe Aortic Stenosis in Patients ?70 to 75 Years*
1 . Patient at high risk for cardiac surgery
a . Cardiac reasons
b . Noncardiac reasons
2 . Patient with limited life span
a . Cardiac reasons nonvalve related
b . Noncardiac reasons
3
. Patient in urgent need for noncardiac surgical procedures
4 . Cardiac surgery undesirable for noncardiac reasons
5 . Patient with moderate to severe CHF and LV dysfunction
6. Patient with severe CHF of uncertain origin and aortic stenosis of
uncertain severity
7 . Patient refusal of surgery
l . In experienced and skilled centers, valvuloplasty is the procedure of
first choice for most patients, particularly patients with a mobile,
nonthickened valve
*The techniques, results and, therefore, indications and contraindications
are still evolving . CHF = congestive heart failure ; LV = left ventricular .
known to be associated with a very high mortality rate ;
about 33% have valve areas of 0.8 to 0.  cm 2 , which,
depending on body size, could still represent severe stenosis
(Table 6) ; and only 25% of patients have moderate stenosis
(valve area
>1 .0
cm 2 ) ( Table 10). The alleviation of severe
heart failure with small increases in aortic valve area was
also predicted (2) and subsequently proved by the two
patients with cardiogenic shock reported by Desnoyers et
al . ; (86) however, in the latter report, both patients had a
poor "late" outcome, probably because the valve area
achieved was only 0 .5 and 0 .6 cm 2 , respectively . Thus, to
achieve better late results, it is important that, once the
Table 12. Relation of Doppler to Cardiac Catheterization Gradient and Valve Areas
in Mitral Stenosis
*From same medical
center . AR = aortic regurgitation .
Range
	
±4 to ±8
±0.30 to ±0 .88
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condition of these patients has improved, they should un-
dergo another intervention (preferably aortic valve replace-
ment) if it is not otherwise clinically contraindicated .
Balloon valvuloplasty for aortic stenosis has been suc-
cessfully performed in combination with valvuloplasty for
mitral stenosis in the same patients (8 , 0) and also with
coronary percutaneous transluminal angioplasty ( 1) .
Suggested guidelines . Balloon valvuloplasty for aortic
stenosis is still in an evolving phase ; improvements in
equipment and technique could have a major impact . A
suggested list of indications for balloon valvuloplasty in
patients ?70 to 75 years of age is given in Table 11 . Although
the procedure is still in an evolving phase, it is clear that it
has an important clinical role in the management of some
patients with aortic stenosis, for example, the patient in
shock (86) and the patient illustrated in Figure 3 . There are
not sufficient data in younger patients to provide any guide-
lines at present .
Mitral Stenosis
Atrial Fibrillation
Digitalis and beta-blocking and calcium channel blocking
agents . Digoxin has been and is the drug of choice for
control of ventricular rate in patients with atrial fibrillation
( 2) .
However, it is much less effective on exercise ( 3),
which is of particular importance in patients with mitral
stenosis . Combination of digitalis with beta-adrenergic
blocking agents is effective in controlling the ventricular
rate ; but for long-term control, beta-adrenergic blocking
agents are not ideal because they may reduce exercise
capacity ( 4) and their negative inotropic effect may pose a
problem in patients with impaired left ventricular function .
Verapamil, a calcium channel blocking agent, controls ven-
2 SE of Regression Equation Estimate
Author Cited Ref. No . of Patients
Mean Mitral Valve
Gradient (mm Hg)
Mitral Valve
Area (cm2 )
1 . Hatle et al .
   25 4 -
2. Stamm et al . 72 26, 27 4 .8 0 .36
3 . Smith et al
.* 100 45 - 0 .40
4 . Grayburn et al .* 101 38 without AR - 0.38
17 with AR
- 0 .42
55 with or without AR - 0.38
5 . Nakatani et al . 102 21 without AR
- 0.56
41 with or without AR - 0.88
6 . Reid et al . 103 46 8 -
53
0.70
27 with Doppler MVA <1.5 cm2 - 0.30
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Table 13 . Mitral Valve Areas Before and After Catheter Balloon Valvuloplasty
tricular rate but also poses problems because of its negative
inotropic effect and its interaction with digoxin, which leads
to a decrease in digoxin renal clearance and, therefore, at
times, to a marked elevation of serum digoxin concentration
and digoxin toxicity ( 5) .
Diltiazem, another calcium channel blocking agent, has
similar electrophysiologic properties to that of verapamil,
resulting in a depression of conduction and prolongation of
refractory lime in the atrioventricular node . However, there
is no significant interaction between digoxin and diltiazem
( 6) . Combination therapy with diltiazem (240 mg/day) and
digoxin (0.25 mg/day) gives good control of ventricular rate
at rest and on exercise ( 7) and results in an improvement in
exercise capacity ( 8) .
Doppler Echocardiography Versus Cardiac
Catheterization for Assessing Severity of
Mitral Stenosis
The range of 2 SE of the regression equation of the mitral
valve gradients and mitral valve areas obtained from Dopp-
ler echocardiography to that obtained from cardiac catheter-
ization is shown in Table 12 .
Catheter Balloon Valvuloplasty
We do not have the long-term results yet but several facts
have rapidly emerged   1) the average mitral valve area is
increased by about 1 .0 c•m2 after balloon valvuloplasty
(Table 13) (Fig . 4) . The increase in valve area is similar to
that observed after surgical mitral commissurotomy (114)
and may be larger than that seen with valve replacement (see
later) . 2) There is a marked improvement in the patients'
functional class that has been objectively documented by
exercise testing (Fig . 5) (115) . 3) The improvement in valve
mm HQ
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0
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Before CBV
II
® After CBV
I
Heart Rate (bpm)
Moon Aortic pressure (mmHg)
Cardiac Output (Liters/min)
Mean Mitral Volvo Gradient (mmHq)
Mitral Valve Area (cmt )
Pre Cev
4--- 1 Sm -1
PostCBV
110  6
 1 80
6.5
6 . 
23
4
1 .1
3.6
*Data from the same center. +It is likely that patients in this series are also included in other series . CBV = catheter balloon valvuloplasty ; NHBLI = National
Heart, Lung, and Blood Institute .
area and functional class is maintained through 1 year of
follow-up (Table 13) (107) . 4) There is a reduction of left
atrial pressure, pulmonary artery pressure and pulmonary
vascular resistance (Fig . 6) (115-117) . These reductions can
Figure 4 . Catheter balloon valvuloplasty (CBV) for severe mitral
stenosis showing major reductions of mitral valve gradient and of
left atrial (LA) pressure . LV = left ventricular; ECG = electrocar-
diogram. (Reproduced by permission of the American Medical
Association [1161 .)
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Mitral Valve Area (cm'-) Mean ± SD
Author Cited Ref.
No . of
Patients Pre-CBV
Immediate 3 to 6 Months 1 Year
Post-CBV Post-CBV Post-CBV
Reid et al . 104, 105 33 1 .0 ± 0
.3
2
.0±0.6
1
.8! 0.7
1
.8±0.4
Palacios et al .* 106 172
0 .  ± 0 .1
(3 months)
2 .0 ± 0 .1 -
Abascal et al .* 107 20 1 . 0 ± 0 .5  1 .62 ± 0.55
Block et al . NHLBI Registryt 108 72 0 .  ±
0 .5
(6 months)
2 .0 ± 1 .0 -
Cequier et al . 10  48 1 .0±0 .4 2 .5±1 .0 2 .1 0.6
Tamai et al . 110 1  0.8±0
.2
(6 months)
1 .4 ± 0
.4 --
Chen et al . 111 54 0 .8 ± 0 .2 2 .0 ± 0.5
Nakatani et al . 112 12 1 .0 ± 0 .2 1 .  ± 0 .6
Inoue et al . 113 515 1 .2 ± 0 .37 1 .  ± 0 .46
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12-
8-
4-
0-
1
l~
mean ± SD
* p
<
.01 vs
before
CBV by ANOVA
BEFORE 1 2
CBV MONTHS AFTER CBV
Figure 5 . Treadmill exercise test (Bruce protocol) demonstrating
significant improvement in exercise capacity within I month of
catheter balloon valvuloplasty (CBV) . The first exercise test after
balloon valvuloplasty was performed at 1 month ; the improvement
persisted through 3 months of the study period . (Figure based on
data of McKay CR et al . ; reproduced by permission of the American
Heart Association, Inc . [115] .)
be dramatically rapid with equally rapid improvement in the
patients' clinical condition (Table 14) . 5) On exercise, the
left atrial and pulmonary artery pressures and mitral valve
gradient are lower after than before valvuloplasty (Fig . 6)
(115) . 6) Left ventricular size and function show no signifi-
cant change (115) . 7) The magnitude of increase of mitral
valve area is dependent on the experience of the operator,
use of double balloon technique, size of the mitral valve
anulus diameter, effective balloon dilating diameter and
morphologic characteristics of the mitral valve (104,107,
116,118) . 8) Doppler estimates of mitral valve area immedi-
ately after balloon valvuloplasty are frequently inaccurate
(118) because of their dependence on transmitral gradient
and atrial and ventricular compliance (11 ) .  ) The incidence
of atrial septal defect after the procedure is as high as
53% (118) ; but many of the defects close by 3 to 12 months,
at which time most are small with a pulmonary to systemic
flow ratio of <1 .5 (104,120,121). Atria] septal defect is
more likely to occur with a small left atrium and with
mitral valve calcification (105,120,121) ; its size can be re-
duced by use of a single as opposed to two separate atrial
punctures and withdrawal of completely deflated balloon
catheters in tandem fashion (122) . 10) There is rapid reduc-
tion of plasma atrial natriuretic peptide levels (123,124) .
11) A prospective randomized clinical trial (114) of 40 pa-
tients has shown that the immediate results of balloon
valvuloplasty and of closed mitral commissurotomy are
similar .
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Figure 6 . Mean mitral valve gradient (A), mean pulmonary artery
wedge pressure (B) and mean pulmonary artery pressure (C) at rest
and on exercise (EX) before and after catheter balloon valvuloplasty
(CBV) for mitral stenosis (November 1 88) . There is a reduction of
all pressures after balloon valvuloplasty at rest and at the same level
of exercise (pre-CBV Ex I-symptom limited [Sx-LTD] versus post-
CBV Ex 1). Three months after balloon valvuloplasty, at a higher
level of exercise (post-CBV, Ex 2, Sx-LTD), pressures are lower
than those present before valvuloplasty (Ex I Sx-LTD) .
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Balloon valvuloplasty versus surgical commissurotomy .
Balloon valvuloplasty for mitral stenosis is somewhat similar
to closed surgical mitral commissurotomy . Results with both
procedures are excellent in patients with a mobile, pliable
and nonthickened valve, which occurs more frequently in
young patients   results in these patients are also likely to be
more durable . Balloon valvuloplasty for mitral stenosis in
patients with a nonmobile, rigid and thickened valve, which
occurs more frequently in older patients, is less satisfactory
and likely to be less durable . However, when the latter group
of patients undergo surgery, at the present time they are
more likely to undergo valve replacement than commissur-
otomy . Thus, if in the latter subgroup, balloon valvuloplasty
delays surgery for only >2 to 5 years, it may not be an
undesirable palliative option . Moreover, the hemodynamic
results may be better than, or at least as good as, that seen
with valve replacement (see later) .
These results are most encouraging and indicate t hat . i n
experienced and skilled centers, double balloon valvulo-
plasty is the procedure of first choice for most patients with
mitral stenosis, particularly those whose valve is mobile and
pliable (Table 11) .
Valvular Regurgitation
Left Ventricular Ejection Fraction on Exercise
in Aortic Regurgitation
Radionuclide angiography has been used to study the left
ventricular ejection fraction at rest and its response to
exercise in patients with severe chronic aortic regurgitation .
Among symptomatic patients, the rest ejection fraction is
below normal in up to 50% of the patients and decreases
RAHIMTOOLA
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Table 14 . Man, Aged 23 Years, Severe Mitral Stenosis . + Mitral Regurgitation (I+ to 2+),
Calcified and Moderately Mobile Valve, Rapid Relief of Severe Hemodynamic Abnormalities After
Catheter Balloon Valvuloplasty (CBV)*
*Left ventricular volumes and ejection fraction were normal both pre-CBV and immediate post-CBV   patient
had spontaneous 3 .5 liter diuresis . Patient was asymplomatic and wanted to walk home, he was discharged from
hospital February 16 . 1 8  and is currently asymplomatic
. (Data reproduced with permission from Kawanishi DT .
Kulick DL . Reid CL . Los Angeles County/University of Southern California Medical Center
.)
with exercise in virtually all   among asymptomatic pa-
tients, the rest ejection fraction is normal in most and
the response to exercise is mixed, with only about 50%
of the patients showing a normal increase (125) . As a result,
it was hoped that the response of left ventricular ejection
fraction to exercise would I) detect latent abnormalities of
left ventricular function, 2) have prognostic value, 3) help
determine the timing of aortic valve replacement in
asymptomatic patients, and 4) predict the results of valve
replacement .
Left ventricular ejection fraction on exercise in valve
regurgitation is dependent on at least two factors   1) state of
myocardial function at rest (126) ; and 2) change of systemic
vascular resistance on exercise (127) . If systemic vascular
resistance declines sufficiently, the left ventricle can meet
the body requirements of increased blood flow on exercise
without changing its ejection fraction (127) . Thus, no rea-
sonable conclusion can be made about myocardial or ven-
tricular function from the change in left ventricular ejection
fraction on exercise without knowledge of the change in
systemic vascular resistance . Therefore, one would expect
that an "abnormal" ejection fraction on exercise without
knowledge of change in systemic vascular resistance would
be of little prognostic value ; and indeed, that is what one
finds . For example, in one study (128) two-thirds of patients
with an "abnormal" ejection fraction on exercise did well
for the 4 year follow-up period, that is . they continued to
remain asymptomatic and to have normal left ventricular
function at rest ; the remaining one-third underwent aortic
valve replacement because they became symptomatic .
Moreover, there is no correlation between this variable and
Pre-C B V
Immediate
(February 14 . 1 8 )
Next Day
(February 15, 1 8 )
Pressures (mm Hg)
Mean right atrium 8 8 4
Pulmonary artery
84/45 (61) 51/2  0 ) 28/1 (27-)
Mean pulmonary artery wedge 43 26
15
Left ventricle 122/1-12 116/6-20
Heart rate (beats/min) 88 77 85
Cardiac output (liters/min) 4 .  6 .3 6 .3
Pulmonary vascular resistance 2 4 160 8 
(dynes/s per cm - `)
Mean mitral valve gradient (mm Hg) ~'  
Mitral valve area (cm'- ) 0 .8 1 .5
Functional class III
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mortality or left ventricular dysfunction after aortic valve
replacement (12 ) .
Vasodilators in Aortic and Mitral Regurgitation
In a previous review (1), findings on vasodilators in mitral
and regurgitation were summarized as follows   1) In aortic
and mitral regurgitation, vasodilators have improved cardiac
hemodynamics and left ventricular function at rest and on
exercise and have also improved functional class . 2) In
symptomatic patients with mitral regurgitation, long-term
therapy with hydralazine, an arteriolar dilator, was disap-
pointing because of a high incidence of side effects and an
unsatisfactory result in the majority of patients . 3) In a single
symptomatic patient with chronic aortic regurgitation, left
ventricular function and symptomatic state had improved
with 12 months of treatment with hydralazine . 4) Additional
long-term studies were needed .
Chronic aortic regurgitation . In a randomized trial of
hydralazine (130), 2 years of therapy with hydralazine in
patients with chronic aortic regurgitation who were asymp-
tomatic or "minimally" symptomatic resulted in an average
reduction of 24 ± 6 ml/m2 in left ventricular end-diastolic
volume index and of 12 ± 3 ml/m2 in end-systolic volume
index and an increase in ejection fraction of 0 .02 ± 0.01 ; all
these changes were statistically significant when compared
with the changes seen in a placebo-treated group . These are
very interesting and helpful data ; however, certain issues
need to be recognized   1) 13 (2 %) of the 45 hydralazine-
treated patients discontinued the drug and 76% experienced
side effects, indicating that this is not a satisfactory drug for
long-term treatment . Interestingly, 44% of the placebo-
treated patients also had side effects; the contents of the
placebo tablets were not given . 2) Both asymptomatic and
"minimally" symptomatic patients, as well as patients with
moderate and severe aortic regurgitation, were studied ;
thus, it is not certain to which of the four subgroups the
results apply. The findings in subgroups of asymptomatic
and symptomatic patients with severe aortic regurgitation
are of considerable interest . 3) Individual data are not
presented ; thus, there is uncertainty regarding the percent of
patients that responded favorably . 4) Some of the improve-
ment was minimal. 5) Definition of "minimally" symp-
tomatic is not given and objective testing of exercise capac-
ity was not performed . Thus, there is uncertainty about what
this subset of patients comprised and also an improvement of
exercise capacity was not studied. 6) This small trial was not
designed to study an improvement in survival or delay in the
need for aortic valve replacement .
In a trial of 1  hydralazine-treated patients with symp-
tomatic, cardiac catheterization and angiographically
proved chronic severe aortic regurgitation (131 and unpub-
lished observations), we were able to demonstrate an im-
provement in exercise capacity and cardiac output and a
reduction of systemic vascular resistance in the treated
group. None of the other hemodynamic or left ventricular
size and function variables (on echocardiography and radio-
nuclide or catheterization angiography) changed significantly
(Table 15). Further review of the data showed that in the
hydralazine-treated group only 37% had an increase of
cardiac output and exercise capacity, and 21% had indeed
had a major reduction in left ventricular end-diastolic vol-
ume index and an increase in ejection fraction . However, the
latter subgroups of patients could not be predicted from
baseline, clinical, exercise, hemodynamic or left ventricular
functional data . These data indicate that hydralazine is of
limited clinical value in symptomatic patients with severe
aortic regurgitation .
Chronic mitral regurgitation . Venodilation with intrave-
nous nitroglycerin has been shown to produce reduction of
left ventricular filling pressure, end-diastolic volume and
regurgitant volume in patients with chronic mitral regurgita-
tion (132), suggesting that venodilators may also have a role
in the treatment of patients with valvular regurgitation .
Implications . Thus, studies done so far have failed to
demonstrate a clear-cut role for arteriolar dilators in the
long-term treatment of patients with chronic severe valve re-
gurgitation . It is possible that other agents, particularly
those that produce both arterial and venous dilation and are
easily tolerated, may be shown to be of greater long-term
value .
Table 15. Long-Term Response to Hydralazine in Chronic Severe
Aortic Regurgitation
JACC Vol . 14, No . I
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Values are mean ± standard deviation . LV = left ventricle ; EDVI =
end-diastolic volume index   ESVI = end-systolic volume index .
Hydralazine (n = 1 )
Initial Late
p
Value
Follow-up (months) I1±3
Treadmill time (min ; Bruce
protocol)
Echocardiograms
6 .3 ± 2 .6 7 .8 ± 2 .8 0 .04
LV End-diastolic dimension (mm) 64 ± 12 61 ± 11
LV End-systolic dimension (mm) 44±  42± 
Fractional shortening (%)
Radionuclide ventriculography
31 ±6 30±7
Rest LV ejection fraction
0 .54
± 12 0 .52 ± 0 .13
Exercise LV ejection fraction 0 .52 ± 10 0 .4  ± 0 .14
Mean aortic pressure  5
± 10 86 ± 10 0.006
Cardiac output (liters/min) 4 .8 ± 1 .1 5 .  ± 1 .2 0.0006
Systemic resistance (dynes/s per
cm-s )
LV Function at angiography
1,511 ± 334 1,124 ± 218 0 .00007
EDVI (ml/m2 ) 161 ± 64 174 ± 60
ESVI (ml/m2 ) 76 ± 45 78 ± 48
Ejection fraction 0.55 ± 0 .13 0.5  ± 0
.17
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Figure 7. Survival curves in patients
with severe aortic stenosis . A, Patients
who had valve replacement (closed cir-
cles) have a better survival than those
treated medically (open circles) . B, Pa-
tients treated with aortic valve replace-
ment (BSA) had a better survival than
that of those treated medically (NH) .
(Reproduced by permission of the
American Heart Association, Inc .
[panel A (42)] and the European Soci-
ety of Cardiology [panel B (38)1 .)
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Improved Survival
There are no prospective randomized clinical trials that
have compared valve replacement with medical treatment .
Two concurrent studies (38,42) compared aortic valve re-
placement with medical treatment for severe aortic stenosis
and showed a large difference in survival in favor of valve
replacement (Fig. 7); the difference suggests that valve
replacement improves survival in symptomatic patients with
severe aortic stenosis . Similar data of Roy and Gopinath
(133) suggest improved survival with closed mitral commis-
surotomy in symptomatic patients with severe mitral steno-
sis who were in functional classes II, III and IV (Fig . 8) .
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Similar data for aortic regurgitation from Schwarz et al . (42)
suggest no benefit of aortic valve replacement up to 4 years
of follow-up .
Left Ventricular Function and Hemodynamics
Aortic valve disease . Aortic stenosis . Patients with severe
aortic stenosis who undergo valve replacement have signif-
Figure 8 . Survival of patients with severe mitral stenosis
. Func-
tional class II patients (panel A) and class III and IV patients (panel
B) who underwent closed surgical commissurotomy had a better
survival than those treated medically . (Reproduced by permission of
the American Heart Association, Inc . [1331 .)
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Table 16 . Effect of Valve Replacement on Left Ventricular Function in Patients With
Aortic Regurgitation
*Changes not statistically significant . AVR = aortic valve replacement . (Data reproduced by permission of the
American Heart Association, Inc . [351 .)
icant early (up to 6 months) and intermediate (0 .5 to 2 years)
improvement in hemodynamics and left ventricular function
and regression of left ventricular hypertrophy (1) . Ejection
fraction improves in most patients ; the most dramatic im-
provement is seen in patients with impaired left ventricular
function who are in clinical heart failure (1,134) . Recent data
of Monrad et al . (135) indicate further late improvement for
up to 8.1 ± 2.  years after aortic valve replacement . At that
time, further small but significant reductions had occurred in
left ventricular systolic and diastolic pressures and end-
diastolic and end-systolic volumes and there was an increase
in cardiac index . Importantly, hypertrophy regressed, left
ventricular mass decreased from 158 ± 33 preoperatively to
114 ± 27 g/m2 (at 1 .6 ± 0.5 years postoperatively, p < 0 .01)
and to  7 ± 28 g/m 2 at 8 .1 ± 2 .  years (p < 0 .01) after valve
replacement .
Aortic regurgitation . Patients with severe aortic regurgi-
tation who undergo valve replacement also have significant
early and intermediate improvement in hemodynamics and
regression of left ventricular hypertrophy, and in many
patients, increase in ejection fraction (1) . Data of Monrad et
al . (135) indicate that late (8 .1 ± 2 .  years) after aortic valve
replacement, there are further reductions in left ventricular
end-diastolic and end-systolic volumes and mass (Table 16) .
Recent data of Bonow et al . (136) show that late (3 to 7 years
Table 17 . Effects of Valve Replacement on Left Ventricular Function in Patients With Aortic Regurgitation
JACC Vol . 14, No . I
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[mean 5]) after aortic valve replacement, left ventricular
dimension decreases further and ejection fraction increases
in patients with normal ejection fraction preoperatively and
not in those with abnormal ejection fraction preoperatively
(Table 17) . It was believed that late improvement in left
ventricular ejection fraction was more likely to occur in
those who had an improvement early after valve replace-
ment (136) but apparently without accompanying late
changes in ventricular dimension or mass (137) . However,
late improvement in ejection fraction occurred only in pa-
tients with normal ejection fraction preoperatively and these
patients indeed did have a further reduction of left ventric-
ular end-diastolic dimension (Table 17) (136). Earlier data of
Bonow et al. (138) had shown that abnormal preoperative
left ventricular ejection fraction in aortic regurgitation usu-
ally normalized if the preoperative abnormality had been
present for <_ 14 months ; if the preoperative ejection fraction
had been abnormal for 18 months or longer, it usually did not
improve after valve replacement .
Mixed aortic stenosis/regurgitation . Data from the Vet-
erans Administration cooperative study indicate that se-
verely depressed preoperative left ventricular ejection frac-
tion (_<0.35) increases after aortic valve replacement in
patients with mixed aortic stenosis and aortic regurgitation
(ejection fraction preoperatively 0.31 ± 0.05, postopera-
LVEF = left ventricular ejection fraction ; other abbreviations as in Tables 15 and 16
. (Data reproduced by permission of the American Heart Association .
Inc . [136] .)
Before
Operation p Value
6 to 8
Months After
AVR p Value
5 Years
(range 3 to 7)
After AVR
Normal LVEF before AVR (n = 22)
LV end-diastolic dimension (mm) 75 ± 6 <0
.001 53 ± 6 <0 .05 51 ± 5
LV muscle cross-sectional area (cm) 36 ± 4 <0 .001
26 ±
5 NS
26 ± 5
LV ejection fraction (%) 52 ± 8
<0 .001 61 ± II <0 .01 68 ± II
Abnormal LVEF before AVR (n = 3 )
LV end-diastolic dimension (mm) 75 ± 7 <0 .001
57 ±   NS 57 ± 11
LV muscle cross-sectional area (cm'-)
34
± 7 <0
.001 27 ± 8 NS
26 ± 8
LV ejection fraction (%)
3  ± 6 <0 .005 46 ±
1
5
NS 4  ± 1 
Controls
Before
Operation
After AVR
1 .6 ± 0 .5 years 8 .1 ± 2 .  years
LV End-diastolic volume index
(M
I/
M
2)
 3 ± 14 225 ± 4  123 ± 36 111 ± 53
LV End-systolic volume index
(M I/ M 2)
31
±     ±35 51±30 46±47
LV Ejection fraction (%)* 67 ± 7 57±I1 61 ±   64 ± 14
LV Muscle mass index (g/m2) 85 ±   1 1 ± 36 128 ± 2  113 ± 35
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Table 18 . Hemodynamics and Left Ventricular Function Before and After Mitral Valve Replacement From the Veterans Administration
Cooperative Study
tively 0.52 ± 0.10 ; p < 0 .001) . In this regard, the response of
these patients appears to be more like that of patients with
aortic stenosis (134) than like that of patients with aortic
regurgitation (13 ) .
Mitral valve disease . Data from the Veterans Administra-
tion Cooperative Study (13) show that patients with mitral
stenosis have significant improvement in hemodynamics ; left
ventricular function does not change . Mitral valve area
increased from 1 .2 ± 0 .4 to 1 .8 ± 0.6 cm
2
(Table 18) . In
patients with combined mitral stenosis and mitral regurgita-
tion, regurgitant volume was reduced and the calculated
value area remained unchanged . Patients with mitral regur-
gitation had significant improvement in hemodynamics and
reductions of left ventricular end-diastolic and regurgitant
Table 1  . Aortic Homograft Primary Valve Failure
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*<0.001 comparison of preop with post-MVR   tp < 0 .01 ; fp < 0 .05 . LV = left ventricular   PA = pulmonary artery ; MVR = mitral valve replacement .
(Reprinted with permission from Crawford MH et al . [13] and unpublished observations .)
volumes; ejection fraction decreased from 0 .56 to 0.45 (p <
0.001) (Table 17) .
Mechanical Versus Bioprosthetic Valves
Two prospective randomized clinical trials (the Edin-
burgh (5) and the Veterans Administration (4) cooperative
studies) have compared a mechanical prosthetic valve with a
bioprosthetic valve. Up to 7 years after surgery, there were
no significant differences in the results with regard to sur-
vival, reoperation and valve-related complications. Thus,
factors other than the type of prosthesis evaluated were
more important in determining the intermediate (5 to 7 years)
results of valve replacement .
Valve Failure
No. of
Author Cited Ref.
Valve Characteristics Patients 5 Years % 10 Years % 15 Years %
at 20 years
*Failure = incidence of aortic incompetence   high risk = donor age >55 years
  recipient's age <15 years ; recipient's aortic root size >30 mm . tThere were
many statistically significant patient-related factors that were different between the two groups
. Failure = reoperation for valve degeneration . $Failure =
reoperation or death
.
1 . Barrat-Boyes et al . 147 Antibiotic sterilized valve*
All patients 252 4 1  54
Low risk 144 1 13 38
High risk 108 10 35
60
2 . O'Brien et al . 148 Allograft aortic valvet
Preservation a) Fresh 4°C
124 - 11 41
b) Viable cryopreserved 1 2 0 0
3 . Matsuki et al . 14  Aortic homografts$
Several preservation techniques 555 - 43 .2 ± 10% 87 .6 ± 4.8%
Mitral Stenosis
Mitral
Stenosis/Regurgitation Mitral Regurgitation
Preop Post-MVR Preop Post-MVR Preop Post-MVR
Patients (no
.)
33 23
48
LV end-diastolic pressures (mm Hg) I1 ± 5 12 ± 6 14±6 13±7 18±8 12±6*
Mean PA wedge pressures (mm Hg) 36 ± 15 28 ± 14* 30 ± 12 25 ± 11 2  ± 11 22 ±  *
Mean systolic PA pressures (mm Hg) 54 ± 24 42 ± 22* 47 ± 18
36 ± 15t 43 ± 16 33 ± 13*
Cardiac index (liters/min per m 2 ) 2 .1 ± 1 .5 2 .3 ± 0 .6 2 .3 ± 0 .6 2 .3 ± 0 .5 2 .5 ± 1 .0 2 .7 ± 0 .7
LV end-diastolic volume index (
M I/M2)
7  ± 18 72 ± 24 10  ± 55
85 ± 25 117 ± 51 8  ± 27*
LV end-systolic volume index (ml/m'- ) 41 ± 13 3  ± 21 54 ± 30 45 ± 22 54 ± 42 50 ± 25
LV ejection fraction 0 .48 ± 0 .10 0.47 ± 0 .14 0.51 ± 0 .13 0 .4  ± 0 .13 0.56 ± 0 .15 0 .45 ± 0 .l3f
Mitral regurgitant volume (ml) 53 ± 68 18 ± 22t
5  ± 45 11 ± 17#
Regurgitant volume/end-diastolic
volume
0.37±0.34 0.1 ±0 .201 0.4 ±0 .31 0.12±0 .17$
Mitral valve gradient (mm Hg) 15 ± 7 8 ± 3* 12±5 7±4
Mitral valve area (cm2 ) 1 .2 ± 0 .4 1 .8 ± 0 .6* 1 .8 ± 2 .2 1 .  ± 0
.5
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Table 20 . Porcine Bioprosthetic Failure Rate*
*Based on diagnosis at valve replacement or by pathologic examination, or both .
Role of anticoagulant therapy . Both trials failed to con-
firm that thromboembolism was a greater hazard with me-
chanical valves than with bioprosthetic valves, probably
because the risks of thromboembolism in valvular heart
disease are multifactorial (3) . The major difference between
the two trials was the incidence of anticoagulation-related
bleeding. In the Veterans Administration study (4), the
incidence of anticoagulation-related bleeding was 4% to 5%
per year; on the other hand, the Edinburgh study (5) re-
ported that complications of bleeding were rare and that
of anticoagulation was only 1% to 1 .5% per year . In the
Veterans Administration study (4), the recommended
level of anticoagulation was a prothrombin time 2 .0 to 2 .5
times control, which is much higher than is usually recom-
mended in patients with a prosthetic heart valve (pro-
thrombin time 1 .6 to 1 .  times control) (3) . Prothrombin
times >2.0 times control increase the incidence of bleeding
without a further reduction in the incidence of thromboem-
bolism. Other differences between the studies, such as
patient-related and health care delivery factors (Table 2),
probably account for most of the observed differences be-
tween the two trials .
Indications for anticoagulation . It needs to be reempha-
sized that all mechanical valves in the patients who do not
receive anticoagulation or receive only aspirin or dipyridam-
ole, or both, are associated with a very high or a high
incidence of thromboembolism (1,7,17,140-146) . Therefore,
patients with any type of mechanical prosthetic heart valve
must receive long-term anticoagulation with sodium warfarin
unless there is a specific contraindication to its use .
JACC Vol. 14, No . I
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Mitral Valve Repair
Galloway et al. (14) recently presented an extensive
review of mitral valve reconstruction for mitral regurgita-
tion . The operative mortality ranges from 2 .3% to 8%; the
mortality rate at 5 years ranges from 8% to 40% and at   to
10 years from 18% to 27% ; and late valve replacement rates
at 5 years range from 3% to 16% . The incidence of throm-
boembolism ranges from 0 .2% to 1 .8%/year ; the incidence at
5 years is 3% to 6% . The incidence of late endocarditis is
very low (14) .
Durability of Valve Replacement Material
Aortic homografts (Table 1 ) . Barrat-Boyes et al. (147)
reported on 248 patients followed up for   to 16 .5 years
(mean 10.8) and showed that the homograft valve failure rate
was 1 % at 10 years and 54% at 15 years ; it was lower in the
low risk group but at 15 years was still 38% . O'Brien et al .
(148) presented data on homografts preserved by two dif-
ferent techniques ; viable allografts cryopreserved in liquid
nitrogen at -1 6°C did not degenerate up to 15 years of
follow-up. Matsuki et al . (14 ) presented data on homografts
inserted between 1 64 and 1 86 . The linearized failure rate
was 4.8 ± 0.4%/year for 20 years ; the failure rate was very
low up to 4 to 5 years and then was steep and steady up to 18
years. The incidence of homograft endocarditis is probably
low in the first year (147,148); it still was 8% to 11% at 15
years and 17 .3% at 20 years (147-14 ), which may not be
significantly different from that of other valve replacement
Author Cited Ref.
No. of
Patients
10
Years
12 to 12 .5
Years
15
Years
Mitral
Foster et al . 150 111 25 ± 6% 42 ± 8% 60 ± 12%
Gallo et al. 151 1 3 35 ± 5% 48 ± 5%
Jamieson et al . 152 50  27 .  ± 4 . % - -
Gallucci et al . 153 502 5  ± 5.5%
Magilligan et al . 154 562 2  * 1 .6% - 70 ± 13%
Aortic
Gallo et al . 151 126 30 ± 7% 42 ± 6%
Jamieson et al . 152 572 16 .  ± 3.7% - -
Gallucci et al . 153 1 6 - 63 ± 10%
Magilligan et al . 154 47  24 ± 3 .4% - 63 ± 18%
Multiple valves
Jamieson et al . 152 11 l 34 .5 ± 7.8%
Galluci et al . 153 71 51 ± 13%
Single and multiple valves
Spampinato et al . 155 1 .0 8 14 .  ± 2.0% 3  .4 ±  .6%
Approximate average incidence 25% 45% 65%
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Figure   . Eighteen to 20 year survival after mitral valve replace-
ment in 458 patients (A) and aortic valve replacement in 660 patients
(B) using the Silastic-ball Starr-Edwards prosthetic heart valves
(mitral no . 6120 ; aortic no . 1260) . (Reproduced by permission of A .
Starr, Heart Institute at St . Vincent Hospital and Medical Center,
Portland, Oregon .)
devices . However, a most interesting finding in these studies
is the very low thromboembolic rate,   ~4% up to 15 years .
Porcine bioprosthetic valves (Table 20). The primary tis-
sue failure rate of bioprosthetic valves ranges from 24% to
35% at 10 years (in one study it was 17% for aortic valve
replacement), is 42% to 48% at 12 years, and 60% to 70% at
15 years (147-155). Primary tissue failure rate is very low in
the first 5 years (2% to 3% at 5 years), with a steady rise in
years 6 to 10 and a marked rise after year 11 . The failure rate
was statistically significantly higher for mitral valves in only
one series (152) . Patients aged <_30 to 35 years are at higher
risk (152) and those aged >_50 to 60 years are at lower risk
(152,153) for bioprosthetic valve failure .
The incidence of thromboembolism is very low with
mitral valve repair and aortic homografts, and that of "late"
endocarditis is very low with mitral valve repair (see earlier) .
Porcine bioprostheses do not share these advantages ; one
reason for this may be that metallic and other materials are
incorporated in the fabrication of the porcine prosthetic
heart valves .
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Table 21. Long-Term Results With Silastic Ball Starr-Edwards
Prosthetic Heart Valve
Mitral 6120 Aortic 1260
at 20 Years at 15 Years
Data of Albert Starr reprinted by permission .
However, both porcine bioprostheses and homografts
have a significant and major problem of valve degeneration,
which for porcine bioprostheses averages approximately
<5% at 5 years, 25% at 10 years, 45% at 12 years and 65% at
15 years (Table 20) . Additional studies of cryopreserved
viable allografts that confirm findings of O'Brien et al . (148)
are needed . The reported incidences of degeneration refer to
those confirmed at operation or pathologic examination, or
both, of explanted valve or at autopsy ; and thus, the actual
clinical incidence of valve degeneration may be higher .
These data mandate a careful reevaluation of the indications
and use of biologic material as valve replacement substi-
tutes .
Mechanical valves . It is clear that at least some of the
mechanical valves are durable ; the one with the longest
proved record is the Silastic-ball Starr-Edwards valve (Fig .
 ) . Structural failure has been virtually nonexistent in the 20
to 22 years of use of this valve at a time when the device has
not undergone any significant change . There are no good
data to show that any valve replacement device is superior to
the Silastic-ball Starr-Edwards valve in overall performance ;
the long-term results of its use are shown in Table 21. It
needs to be reemphasized that results of valve surgery are
dependent on many factors (Tables 1 and 2) (3) ; one should
avoid making inappropriate comparisons and thereby arriv-
ing at inappropriate conclusions .
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